Application
Fig1: Western blot analysis of Apolipoprotein E on human kidney lysates using anti-Apolipoprotein E antibody at 1/1,000 dilution.Application
Fig2: Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-Apolipoprotein E antibody. Counter stained with hematoxylin.Application
Fig3: Immunohistochemical analysis of paraffin-embedded human liver tissue using anti-Apolipoprotein E antibody. Counter stained with hematoxylin.Application
Fig4: Immunohistochemical analysis of paraffin-embedded human kidney tissue using anti-Apolipoprotein E antibody. Counter stained with hematoxylin.Application
Fig5: Immunohistochemical analysis of paraffin-embedded mouse liver tissue using anti-Apolipoprotein E antibody. Counter stained with hematoxylin.| Product Name | Apolipoprotein E [SC0536] |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | AD2 antibody Apo-E antibody APOE antibody APOE_HUMAN antibody APOEA antibody Apolipoprotein E antibody Apolipoprotein E3 antibody ApolipoproteinE antibody Apoprotein antibody LDLCQ5 antibody LPG antibody |
| Product description | Apolipoprotein-E (apoE) is a protein component of plasma lipoproteins that mediates the binding, internalization and catabolism of lipoprotein particles. It can serve as a ligand for several lipoprotein receptors, including the LDL (ApoB/E) receptor and the hepatic apoE (chylomicron remnant) receptor. apoE is produced in most organs and occurs in all plasma lipoprotein fractions, constituting 10-20% of VLDL (very low density lipoprotein) and 1-2% of HDL (high density lipoprotein). Three major isoforms of apoE have been described in human (E2, E3 and E4) which differ by only one or two amino acids. Estrogen receptor has been shown to upregulate apoE gene expression via the ERa-mediated pathway, indicating a potential role for apoE in atherosclerosis. This is consistent with studies in mice in which plasma apoE levels were raised, thereby protecting the mice from diet-induced atherosclerosis. apoE has also been shown to be a potent inhibitor of proliferation and thus may play a role in angiogenesis, tumor cell growth and metastasis. |
| Immunogen | recombinant protein |
| Clonality | Monoclonal |
|---|---|
| Isotype | IgG |
| Host Species | Recombinant rabbit |
| Tested Applications | WBICC/IFIHCIP |
| WB:1:1,000-1:5,000 ICC:1:50-1:200 IHC:1:50-1:200 |
|
| Species Reactivity | HumanMouse |
| Concentration | 1mg/ml |
| Alternative Names | AD2 antibody Apo-E antibody APOE antibody APOE_HUMAN antibody APOEA antibody Apolipoprotein E antibody Apolipoprotein E3 antibody ApolipoproteinE antibody Apoprotein antibody LDLCQ5 antibody LPG antibody |
|---|---|
| Molecular Weight(MW) | 36 kDa |
| Cellular Localization | Secreted. |
Application
Fig1: Western blot analysis of Apolipoprotein E on human kidney lysates using anti-Apolipoprotein E antibody at 1/1,000 dilution.
Application
Fig2: Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-Apolipoprotein E antibody. Counter stained with hematoxylin.
Application
Fig3: Immunohistochemical analysis of paraffin-embedded human liver tissue using anti-Apolipoprotein E antibody. Counter stained with hematoxylin.
Application
Fig4: Immunohistochemical analysis of paraffin-embedded human kidney tissue using anti-Apolipoprotein E antibody. Counter stained with hematoxylin.
Application
Fig5: Immunohistochemical analysis of paraffin-embedded mouse liver tissue using anti-Apolipoprotein E antibody. Counter stained with hematoxylin.| Positive Control | Human tonsil tissue, human liver tissue, human kidney tissue, mouse liver tissue. |
|---|---|
| Application Notes | WB:1:1,000-1:5,000 ICC:1:50-1:200 IHC:1:50-1:200 |
| Form | Liquid |
|---|---|
| Storage Instructions | Store at +4℃ after thawing. Aliquot store at -20℃ or -80℃. Avoid repeated freeze / thaw cycles. |
| Storage Buffer | 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide. |
